Phase 1:

Initial studies in human volunteers to establish the safe dose level of a drug.

Phase 2a:

"Proof of Concept" clinical studies in relevant patient populations.

About Ischemix

Ischemix is a privately-held drug discovery company with a portfolio of small molecule therapeutic compounds. The first of these compounds is targeted to reduce cell death and organ damage due to initial interruption and subsequent resumption of blood flow associated with cardiac surgeries and interventional procedures such as percutaneous coronary intervention ("PCI" or "angioplasty") and coronary artery bypass grafting ("CABG") as well as myocardial infarction ("MI" or heart attack).

The Company was founded in 1999 based on research conducted at laboratories associated with the Massachusetts Institute of Technology and Harvard University. We remain small and highly focused, with emphasis on clinical efficacy in animal models of ischemia-reperfusion injury.

Ischemix completed a 40 subject Phase 1 safety study in 2007 under an Investigational New Drug (IND) filing with the US Food and Drug Administration (FDA) with its lead compound, CMX-2043. In early 2010 Ischemix initiated a multi-center Phase 2a clinical trial with CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective PCI procedures.